Biotech grieves over Tachi’s passing; $3 trillion mirage?; Sanofi has a new Pompe drug; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
While I did not personally know Dr. Tachi Yamada, it’s clear from the outpouring of tributes just how many lives he touched and changed. Once again, our deepest condolences to his family and loved ones.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.